Clinical-stage biopharmaceutical company Sagimet Biosciences could see its treatments reach a breakout stage, which could send its share price soaring, according to Goldman Sachs. The stock has been publicly traded since July 14, and it's trading slightly below its IPO level. Investors are focused on upcoming biopsy results of the second phase of the denifanstat study on liver fat levels, said Tan. Positive results from this phase would support advancement into a pivotal phase three study, she added. The "role of FASN in other indications could offer upside," Tan noted.

---

Persons: Goldman Sachs, NASH, Andrea Tan, Tan, Denifanstat, FASN, — CNBC's Michael Bloom Organizations: Sagimet Biosciences